❮
❯
Product info
- Product name:Immunoassay Analyzer Machine
- Product code:CCL141
Packaging Specifications
- Outer Packaging Size:0.4 × 0.39 × 0.24 m
- Gross Weight:7 kg
- Net Weight:0 kg
- Volume:0.04
Description
| Cardiac | ||||||
| cat#. | Product item | Specimen | Reaction Time | Measure Range | Clinical Range | Itended Use |
| 1 | cTnI | WB/Serum/Plasma | 12min. | 0.1-40ng/ml | <0.3ng/ml | several heart diseases including myocardial infarction and heart failure. |
| 2 | Myo | WB/Serum/Plasma | 12min. | 5-400ng/ml | <58ng/ml | acute myocardial infarction (AMI) in early stage. |
| 3 | CK-MB | WB/Serum/Plasma | 12min. | 1-200ng/ml | <5ng/ml | acute myocardial infarction (AMI) in early stage. |
| 4 | NT-proBNP | WB/Serum/Plasma | 10min. | 20-35000pg/ml | Under 75：0~347pg/mL， Over 75：0~449pg/mL | heart failure . |
| 5 | D-Dimer | WB/Plasma | 10min. | 40-10000ng/ml | <500ng/ml | disseminated intravascular coagulation (DIC),deep vein thrombosis (DVT),pulmonary embolism (PE), myocardial infarction, cerebral infarction, etc. |
| 7 | ST2 | WB/Serum/Plasma | 10min. | 10-400ng/ml | <35ng/ml | heart failure . |
| Inflammation | ||||||
| 11 | CRP / hs-CRP | WB/Serum/Plasma | 3min. | 0.5-200mg/L | CRP<10mg/L，hs-CRP<1mg/L | nonspecficity inflammatory marker. |
| 12 | SAA | WB/Serum | 5min. | 1-200mg/L | <10mg/L | inflammation&infection. |
| 13 | PCT | WB/Serum/Plasma | 10min. | 0.2-100ng/ml | <0.5ng/ml | Sepsis |
| 15 | IL-6 | WB/Serum/Plasma | 10min. | 5-4000pg/ml | 10pg/ml | diabetes,rheumatoid arthritis,etc |
| Thyroid Hormone | ||||||
| 17 | TSH | WB/Serum/Plasma | 15min. | 0.3-100mU/L | 0.3-4.2mU/L | hyperthyroidism and hypothyroidism |
| 18 | TT3 | WB/Serum/Plasma | 15min. | 0.5-10nmol/L | 1.23-3.07nmol/L | thyroid dysfunction |
| 19 | TT4 | WB/Serum/Plasma | 15min. | 5-300nmol/L | 66-181nmol/L | thyroid dysfunction |
| 20 | FT3 | WB/Serum/Plasma | 15min. | 1-50pmol/L | 3.1-6.8pmol/L | thyroid dysfunction |
| 21 | FT4 | WB/Serum/Plasma | 15min. | 5-100pmol/L | 12-22pmol/L | thyroid dysfunction |
| Tumor Maker | ||||||
| 22 | AFP | WB/Serum/Plasma | 10min. | 2.5-200ng/ml | <20ng/ml | pregnancy cancer |
| 23 | CEA | WB/Serum/Plasma | 10min. | 1-200ng/ml | <5ng/ml | colon cancer, colorectal cancer,etc. |
| 26 | PG II | WB/Serum/Plasma | 10min. | 1-100ug/L | PGI/PGII>3.0 | gastric abnormalities |
| 27 | PG I | WB/Serum/Plasma | 10min. | 2.5-200ug/L | >70ng/ml | gastric abnormalities |
| 28 | TPSA | WB/Serum/Plasma | 10min. | 0.5-40ng/ml | <4ng/ml | prostate cancer |
| 29 | FPSA | WB/Serum/Plasma | 10min. | 0.1-10ng/ml | <1ng/ml | prostate cancer |
| 30 | CA12-5 | WB/Serum/Plasma | 10min. | 20-500U/ml | <35U/ml | ovarian cancer |
| 31 | CA15-3 | WB/Serum/Plasma | 10min. | 10-400U/ml | < 25 U/mL | breast cancer |
| 33 | CA19-9 | WB/Serum/Plasma | 10min. | 10-400U/ml | < 27 U/mL | pancreatic cancer |
| Fertility | ||||||
| 36 | β-HCG | WB/Serum/Plasma | 10min. | 2-100000mIU/ml | <5 mIU/mL | early pregrancy. |
| 37 | AMH | WB/Serum/Plasma | 10min. | 0.1-16ng/ml | Male: 20-60 years old, 0.92-13.89 ng/mL Female: 20-29 years old, 0.88-10.35 ng/mL 30-39 years old, 0.31-7.86 ng/mL 40 -50 years old, <5. 07 ng/mL | ovarian reserve level |
| 38 | LH | WB/Serum/Plasma | 15min. | 1-100mIU/ml | Male: 1.81-8.16 mIU/mL; Female: Follicular phase : 2.95 -13.65 mIU/mL Ovulation phase: 13.65-95.75 Miu/mL Luteal phase: 1.25-11.00 mIU/mL Menopause phase: 8.74 -55.00 mIU/mL | reproductive dysfunction |
| 39 | FSH | WB/Serum/Plasma | 15min. | 1-100mIU/ml | Male: 1.50-12.40 mIU/mL Female: Follicular phase : 4.46-12.43 mIU/mL Ovulation phase: 4.88-20.96 mIU/mL Luteal phase: 1 .95-8.04 mIU/mL Menopause phase: 20.00-98.62 mIU/mL | reproductive system |
| 40 | Testosterone | WB/Serum/Plasma | 15min. | 0.2-15ng/ml | Male: 20-49 years old, 1.91-8.41 ng/mL >50 years old, 1.61-8.01 ng/mL Female: 20-49 years old,<0.80ng/mL >50 years old, <0.71 ng/mL | sexual hormone disturbance and hypogonadism. |
| 41 | Progesterone | WB/Serum/Plasma | 15min. | 1.4-60ng/ml | Male: 0-1.5ng/mL Female: Follicular phase : 0-1.9ng/mL Ovulation phase: 0-12ng/mL Luteal phase: 1.7-28.7ng/mL Menopause phase:0-1.4ng/mL Pregnancy:11-60ng/mL | pregrancy progesterone |
| 42 | PRL | WB/Serum/Plasma | 15min. | 1-200ng/ml | Male: 3.45-17.42 ng/mL Female (non-pregnant): 4.60-25.07 ng/mL | breastfeeding&abnormal lactation |
| 44 | E2 | WB/Serum/Plasma | 15min. | 9-3000pg/ml | Male: <85 pg/mL Female: Follicular Phase: 12-262 pg/mL Ovulation: 40-396 pg/mL Luteal Phase: 21-381 pg/mL Menopause: <190 pg/mL Pregnancy: >145 pg/mL | ovarian vitality. |
| Gastrointestinal | ||||||
| 47 | FOB+TRF | fecal specimens | 10min. | qualitative | qualitative | gastrointestinal hemorrhage. |
| Infection | ||||||
| 48 | Covid-19 Antigen | nasal swab, throat swab or nasal wash/aspirate specimens | 15min. | qualitative | qualitative | respiratory tract |
| 49 | Covid-19 Ab IgG/IgM | WB/Serum/Plasma | 15min. | qualitative | qualitative | respiratory tract |
| 50 | FluA Antigen | nasal swab, throat swab or nasal wash/aspirate specimens | 15min. | qualitative | qualitative | respiratory tract |
| 51 | FluB Antigen | nasal swab, throat swab or nasal wash/aspirate specimens | 15min. | qualitative | qualitative | respiratory tract |
| 52 | HPAntigen | nasal swab, throat swab or nasal wash/aspirate specimens | 15min. | 0.05-100ng/mL | <0.1ng/mL | pylori infection |
| 53 | HP IgG | WB/Serum/Plasma | 15min. | 3-80ng/mL | <5ng/mL | pylori infection |
| Renal injury | ||||||
| 54 | CysC | WB/Serum/Plasma | 5min. | 0.4-9mg/L | 0.5-1.1mg/L | renal function |
| 55 | NGAL | Urine | 10min. | 10-1500ng/mL | <132ng/mL | acute kidney injury. |
| 56 | MAU | Urine | 10min. | 5-300mg/l | <20mg/l | renal function. |
| Diabetes | ||||||
| 59 | HbA1c | WB | 10min. | 4%-14% | 4%-6% | diabetes |
| 60 | Insulin | WB/Serum/Plasma | 15min. | 1 – 200 µU/mL | 5-20µU/mL | diabetes |
| 61 | C-peptide | WB/Serum/Plasma | 15min. | 0.1 - 16ng/mL | 0.33-3.76ng/mL | diabetes |
| Brain diseases | ||||||
| 62 | S100β | WB/Serum/Plasma | 10min. | 0.05-10ng/ml | <0.2ng/ml | Cerebral infarction, cerebral injury. |
| Nutritional metabolism | ||||||
| 63 | FERR | WB/Serum/Plasma | 5min. | 10-500ng/mL | Male:24ng/mL~335ng/mL, Female:11ng/mL~307ng/mL | iron metabolism related diseases, such as hemochromatosis and iron deficiency anemia |
| 64 | VD | WB/Serum/Plasma | 15min. | 30-120ng/mL | 30-70ng/mL | osteoporosis |
| 65 | VB12 | WB/Serum/Plasma | 15min. | 50-2000pg/mL | 200-900pg/mL | VB12 deficiency |
| Autoimmune | ||||||
| 66 | Total IgE | WB/Serum/Plasma | 10min. | 0.05-10mg/L | 0.1-0.9mg/L | allergy, rickets |
| Rheumatoid | ||||||
| 67 | Anti-CCP | WB/Serum/Plasma | 15min | 7-300U/mL | ≤ 7 U/mL | Rheumatoid Arthritis |
| 68 | RF | WB/Serum/Plasma | 15min | 3-120IU/mL | ≤ 3IU/mL | Rheumatoid Arthritis |
| 69 | ASO | WB/Serum/Plasma | 15min | 100-1000IU/Ml | ≤ 100IU/mL | |
no comments